Figure 6

The effects of ciglitazone on NF-κB activation and CXCL10 gene transcription. Confluent serum-deprived asthmatic (A) and non-asthmatic (NA) ASMC were treated with the PPARγ antagonist GW-9662 and/or ciglitazone prior to and during stimulation with cytomix and A) IκB-α degradation, B) NF-κB p65 DNA binding activity and C) CXCL10 mRNA levels determined at 15 and 30 min (A and B) or 3 h using RT-PCR (C) respectively.